According to the US Centers for Disease Control and Prevention, prostate cancer is the second leading cause of cancer death among men. One of the standard approaches for the diagnosis and treatment of ...

SINGAPORE, March 5, 2022 /PRNewswire/ -- Biobot Surgical is excited to announce U.S. FDA 510(k) clearance of the iSR'obot Mona Lisa 2.0. The new robotic assisted transperineal needle-guidance system ...

Excluding systematic biopsy in favor of MRI-targeted biopsy in men with elevated prostate-specific antigen (PSA) levels reduced the probability of detecting clinically insignificant cancers, but at ...

Screening for prostate cancer is burdened by a high rate of overdiagnosis. The most appropriate algorithm for population-based screening is unknown. We invited 37,887 men who were 50 to 60 years of ...

Baseline MRI PI-RADS score suggests prognosis and may improve upfront risk stratification and eligibility for prostate cancer active surveillance. Higher baseline MRI PI-RADS score is associated with ...

Prostate cancers that are missed on multiparametric (mp)MRI are small and potentially not clinically significant, according to an analysis of data from the Prostate MR Imaging Study (PROMIS). "Our ...

Omitting systematic biopsy in men with elevated prostate-specific antigen (PSA) levels and negative MRI results, and performing only targeted biopsy of MRI-positive lesions, eliminated more than half ...

Omitting biopsy in patients with a negative prostate MRI more than halves the diagnoses of clinically insignificant prostate cancer. Detection of clinically insignificant ISUP grade group 1 prostate ...

Dec. 15, 2025 — For decades, when tests suggested that a man might have prostate cancer, the next step was usually a biopsy. The procedure, where a doctor uses a thin needle to collect prostate ...